Dorothee Lebert

Dorothee Lebert currently serves as the Chief Scientific Officer at Promise Proteomics, a pioneering integrated medtech company dedicated to advancing proteomic applications within clinical laboratories. In this strategic role, she spearheads the scientific orientation and development initiatives that drive innovation in diagnostic solutions. Her expertise in proteomics, LC-MS technology, and biochemistry underpins the company's mission to develop highly sensitive and specific diagnostic assays that leverage stable labelled proteins as internal standards, ensuring robust quantification and reproducibility.

At Promise Proteomics, Dorothee oversees key projects focused on integrating cutting-edge LC-MS workflows with novel biomarker discovery and validation, facilitating the translation of proteomic insights into clinically actionable diagnostics. Her leadership extends to managing collaborations with academic institutions, clinical partners, and regulatory bodies, ensuring that the company's solutions meet stringent industry standards and market needs. She actively interacts with commercial teams to align scientific developments with market access strategies, fostering a seamless pathway from innovation to adoption.

With a strong background in in vitro diagnostics (IVD), protein expression, and biopharmaceutical technologies such as monoclonal antibodies and PSAQ, Dorothee brings a comprehensive understanding of the biotechnological landscape. Her expertise in pharmacokinetics and biochemistry enables her to guide the development of diagnostic assays that are not only innovative but also clinically relevant and scalable. Through her leadership, Promise Proteomics aims to revolutionize proteomic diagnostics, ultimately improving patient outcomes through more precise and personalized medicine.